BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24446437)

  • 1. Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption.
    Stuible M; Moraitis A; Fortin A; Saragosa S; Kalbakji A; Filion M; Tremblay GB
    J Biol Chem; 2014 Mar; 289(10):6498-6512. PubMed ID: 24446437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
    Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
    J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis.
    Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N
    Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) mediates periarticular bone loss, but not joint destruction, in murine antigen-induced arthritis.
    Shimizu T; Takahata M; Kameda Y; Endo T; Hamano H; Hiratsuka S; Ota M; Iwasaki N
    Bone; 2015 Oct; 79():65-70. PubMed ID: 26027508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Siglec-15 antibody suppresses bone resorption by inhibiting osteoclast multinucleation without attenuating bone formation.
    Tsukazaki H; Kikuta J; Ao T; Morimoto A; Fukuda C; Tsuda E; Minoshima M; Kikuchi K; Kaito T; Ishii M
    Bone; 2021 Nov; 152():116095. PubMed ID: 34216837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12 kDa (DAP12).
    Ishida-Kitagawa N; Tanaka K; Bao X; Kimura T; Miura T; Kitaoka Y; Hayashi K; Sato M; Maruoka M; Ogawa T; Miyoshi J; Takeya T
    J Biol Chem; 2012 May; 287(21):17493-17502. PubMed ID: 22451653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec-15 on Osteoclasts Is Crucial for Bone Erosion in Serum-Transfer Arthritis.
    Korn MA; Schmitt H; Angermüller S; Chambers D; Seeling M; Lux UT; Brey S; Royzman D; Brückner C; Popp V; Percivalle E; Bäuerle T; Zinser E; Winkler TH; Steinkasserer A; Nimmerjahn F; Nitschke L
    J Immunol; 2020 Nov; 205(10):2595-2605. PubMed ID: 33020147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of obovatol on osteoclast differentiation and bone resorption.
    Kim HJ; Hong JM; Yoon HJ; Kwon BM; Choi JY; Lee IK; Kim SY
    Eur J Pharmacol; 2014 Jan; 723():473-80. PubMed ID: 24334279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption.
    Andes FT; Adam S; Hahn M; Aust O; Frey S; Grueneboom A; Nitschke L; Schett G; Steffen U
    Bone; 2021 Feb; 143():115665. PubMed ID: 33007530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic Dinucleotides Inhibit Osteoclast Differentiation Through STING-Mediated Interferon-β Signaling.
    Kwon Y; Park OJ; Kim J; Cho JH; Yun CH; Han SH
    J Bone Miner Res; 2019 Jul; 34(7):1366-1375. PubMed ID: 30779854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
    Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
    Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoclast 121F antigen expression during osteoblast conditioned medium induction of osteoclast-like cells in vitro: relationship to calcitonin responsiveness, tartrate resistant acid phosphatase levels, and bone resorptive activity.
    Collin-Osdoby P; Oursler MJ; Rothe L; Webber D; Anderson F; Osdoby P
    J Bone Miner Res; 1995 Jan; 10(1):45-58. PubMed ID: 7747630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
    Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
    Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice.
    Hiruma Y; Tsuda E; Maeda N; Okada A; Kabasawa N; Miyamoto M; Hattori H; Fukuda C
    Bone; 2013 Mar; 53(1):87-93. PubMed ID: 23238125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.
    Kim HJ; Yoon HJ; Choi JY; Lee IK; Kim SY
    J Leukoc Biol; 2014 Feb; 95(2):337-45. PubMed ID: 24130113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
    Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
    J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.